Viatris, formed in November 2020 from the merger of Mylan with Pfizer’s Upjohn division, has established an eye care division following the closure of two acquisitions on...
Pfizer has completed the spin-off of its Upjohn Business and combined it with Mylan to form Viatris, which began trading on Nov. 17. On closure of the deal, Pfizer...
Mylan has agreed to buy the related intellectual property and commercialization rights of Aspen Pharmacare’s European thrombosis business for €641.9 million. The company...
US generics specialist Mylan is investing an additional $20 million in Mapi Pharma to support the latter’s ongoing Phase 3 clinical study and eventual commercialization...
13.09.2019
- Abbvie takes over Allergan, Pfizer merges its generics business with Mylan, Takeda integrates Shire — the pharmaceutical industry is making a name for itself in 2019 with several...
10.09.2019
- Is it possible to learn from other industries or are we doomed to repeat the same mistakes in the pharma sector? Not long ago, I came across a Forbes article which described how...
30.07.2019
- New York-based US drugs giant Pfizer is merging its off-patent franchise, Upjohn, with generics specialist Mylan. The deal announced on Jul. 29 and expected to close in mid-2020...
15.05.2019
- A coalition of 44 US states has filed a 500-page lawsuit against 20 leading generic drugmakers supplying the domestic market. The companies are accused of operating a sweeping...
